A61K 47/6803
Drugs conjugated to an antibody or immunoglobulin
Official title: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
A61K47/6803 (Drugs conjugated to an antibody or immunoglobulin) appears on 3,892 US grants and 7,373 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,892
- Published applications
- 7,373
- Assignees
- 1,844
- Inventors
- 10,885
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 2 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 7 | 0 |
| 1983 | 6 | 0 |
| 1984 | 4 | 0 |
| 1985 | 2 | 0 |
| 1986 | 4 | 0 |
| 1987 | 11 | 0 |
| 1988 | 12 | 0 |
| 1989 | 13 | 0 |
| 1990 | 22 | 0 |
| 1991 | 13 | 0 |
| 1992 | 24 | 0 |
| 1993 | 17 | 0 |
| 1994 | 12 | 0 |
| 1995 | 12 | 0 |
| 1996 | 17 | 0 |
| 1997 | 34 | 0 |
| 1998 | 57 | 0 |
| 1999 | 38 | 0 |
| 2000 | 37 | 0 |
| 2001 | 27 | 6 |
| 2002 | 36 | 42 |
| 2003 | 30 | 81 |
| 2004 | 23 | 78 |
| 2005 | 19 | 88 |
| 2006 | 34 | 92 |
| 2007 | 29 | 79 |
| 2008 | 30 | 87 |
| 2009 | 61 | 127 |
| 2010 | 64 | 117 |
| 2011 | 50 | 140 |
| 2012 | 83 | 141 |
| 2013 | 92 | 162 |
| 2014 | 114 | 243 |
| 2015 | 125 | 272 |
| 2016 | 187 | 393 |
| 2017 | 210 | 383 |
| 2018 | 222 | 447 |
| 2019 | 268 | 450 |
| 2020 | 271 | 439 |
| 2021 | 282 | 486 |
| 2022 | 245 | 509 |
| 2023 | 284 | 629 |
| 2024 | 280 | 664 |
| 2025 | 287 | 683 |
| 2026 | 191 | 535 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 47/6811The drug being a protein or peptide1,994
- A61K 47/6807The drug or compound being a sugar, nucleoside, nucleotide, nucleic acid750
- A61K 47/68031The drug being an auristatin693
- A61K 47/68033The drug being a maytansine469
- A61K 47/68035The drug being a pyrrolobenzodiazepine263
- A61K 47/68037The drug being a camptothecin [cpt] or derivatives244
- A61K 47/6805The drug being a vinca alkaloid35
Recent patents
- Muscle targeting complexes and formulations for treating facioscapulohumeral muscular dystrophy6 Oct 2026US 12,752,013 B2Dyne Therapeutics, Inc.
- Disruption of CD28-sialoside ligand complexes to enhance T cell activation6 Oct 2026US 12,752,014 B2The Scripps Research Institute
- Anti-Nectin-4 antibody, conjugate including the same, and application thereof6 Oct 2026US 12,753,230 B2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Camptothecin derivatives29 Sep 2026US 12,747,250 B2ImmunoGen, Inc.
- Methods of treating residual breast cancer with trastuzumab emtansine22 Sep 2026US 12,740,962 B2Genentech, Inc.
- Prefusion-stabilized human parainfluenza virus 3 f proteins8 Oct 2026US 2026/0306613 A1Board of Regents, The University of Texas System
- Delivery of dual payload of mmaf or mmae and tlr7 agonists8 Oct 2026US 2026/0306648 A1The Research Foundation for The State University of New York
- Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab8 Oct 2026US 2026/0306649 A1Agensys, Inc.
- Camptothecin drug conjugate and use thereof8 Oct 2026US 2026/0306650 A1Shanghai Zaimo Biotechnology Co., Ltd.
- Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof8 Oct 2026US 2026/0306651 A1MediLink Therapeutics (Suzhou) Co., Ltd.
Most cited
By later US patents
- Cytotoxic agents comprising maytansinoids and their therapeutic use805US 5,208,020 AImmunoGen, Inc. · 1993
- Lysosomal enzyme-cleavable antitumor drug conjugates653US 6,214,345 B1Bristol-Myers Squibb Company · 2001
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Therapeutic inhibitor of vascular smooth muscle cells562US 5,733,925 ANeoRx Corporation · 1998
- Solubilization of proteins for pharmaceutical compositions using polymer conjugation538US 4,766,106 ACetus Corporation · 1988